ArticleCureus2026
Dual-Site Inflammation During Adalimumab Therapy: Birdshot Chorioretinopathy Complicated by Paradoxical Psoriasis.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Birdshot chorioretinopathy is a chronic posterior uveitis that often requires systemic immunomodulatory therapy, yet biologic agents, particularly tumor necrosis factor alpha (TNF-α) inhibitors, may trigger paradoxical cutaneous inflammation and complicate multidisciplinary management. A 32-year-old man was evaluated for progressive right eye (RE) visual decline and long-standing floaters. Examination showed bilateral posterior uveitis with chorioretinitis and retinal vasculitis, more severe in the RE, with significant cystoid macular edema (CME) and leakage on fluorescein angiography (FA). Infectious and systemic causes were excluded, and human leukocyte antigen A29 (HLA-A29) was not detected. Systemic methylprednisolone induced partial anatomic improvement but was limited by recurrence during tapering and by intraocular pressure (IOP) elevation, prompting escalation with mycophenolate mofetil and later adalimumab therapy for persistent, refractory CME. After an insufficient response, an intravitreal dexamethasone implant achieved edema regression but was followed by ocular hypertension requiring sustained IOP-lowering therapy. During the same treatment course, new-onset palmoplantar pustular and scalp lesions developed, with steroid-dependent fluctuations, and histopathology showed mild spongiotic dermatitis with Langerhans cell microabscesses; the overall presentation was considered consistent with adalimumab-associated paradoxical psoriasis. Cutaneous disease showed only transient benefit from topical therapy and phototherapy, and an interleukin-17 (IL-17) inhibitor was recommended but declined by the patient. This case illustrates how anti-TNF-α therapy may be insufficient for ocular inflammatory control while precipitating paradoxical psoriasis. Optimal outcomes rely on coordinated ophthalmology-dermatovenereology care when ocular disease activity and treatment-emergent skin complications evolve in parallel.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.